This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Tyrer, P.
Right arrow Articles by Bateman, A. W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tyrer, P.
Right arrow Articles by Bateman, A. W.
Advances in Psychiatric Treatment (2004) 10: 389-398
© 2004 The Royal College of Psychiatrists

Drug treatment for personality disorders

Peter Tyrer and Anthony W. Bateman

Peter Tyrer is Professor of Community Psychiatry and Head of the Department of Psychological Medicine at Imperial College (Charing Cross Campus, St Dunstan’s Road, London W6 8RP, UK. E-mail: p.tyrer{at}imperial.ac.uk), and an honorary consultant in rehabilitation psychiatry with Central North West London and West London Mental Health NHS Trusts. He is the current Editor of the British Journal of Psychiatry and Co-Chair of the Section of Personality Disorders of the World Psychiatric Association. Anthony Bateman is a consultant psychiatrist in psychotherapy, research lead of psychotherapy services (Haringey) in Barnet, Enfield and Haringey Mental Health NHS Trust and an honorary senior lecturer at the Royal Free and University College Medical School, London. His interests include treatment of personality disorder and the integration of psychotherapy and psychiatry. Over the past decade he has developed, with Peter Fonagy, a programme for the treatment of borderline personality disorder.

There is some evidence that antidepressants, particularly the selective serotonin reuptake inhibitors and the monoamine oxidase inhibitors, have some benefits in the management of borderline personality disorder, and lesser evidence (partly because of limited trial data) for the benefits of antipsychotic drugs and mood stabilisers. There is not sufficient distinction between the different personality disorders to recommend that any one disorder should be treated by any one drug, and successful treatment is dependent on careful management, sensitive to the patient’s expectations.




This article has been cited by other articles:


Home page
 Adv. Psychiatr. Treat.Home page
J. Sarkar and G. Adshead
Personality disorders as disorganisation of attachment and affect regulation
Advan. Psychiatr. Treat., July 1, 2006; 12(4): 297 - 305.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
A. W. Bateman and P. Tyrer
Services for personality disorder: organisation for inclusion
Advan. Psychiatr. Treat., November 1, 2004; 10(6): 425 - 433.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
A. W. Bateman and P. Tyrer
Psychological treatment for personality disorders
Advan. Psychiatr. Treat., September 1, 2004; 10(5): 378 - 388.
[Abstract] [Full Text] [PDF]